Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Cappuzzo, F. [1 ]
Moreno Garcia, V. [2 ]
Ou, S-H. I. [3 ]
Brandao, M. [4 ]
Sanmamed, M. F. [5 ]
Helissey, C. [6 ]
Wislez, M. [7 ]
Call, J. A. [8 ]
Grisanti, S. [9 ]
Johnson, M. L. [10 ]
Boni, V. [11 ]
Jamme, P. [12 ]
Monnet, I. [13 ]
Siena, S. [14 ]
Yan, C. [15 ]
Barasa, B. [16 ]
Richard, B. [17 ]
Joe, A. K. [18 ]
Laus, G. [18 ]
Felip, E. [19 ]
机构：
[1] IRCCS Ist Nazl Tumori Regina Elena IRE, Med Oncol, Rome, Italy
[2] Hosp Univ Fdn Jimenez Diaz, START Madrid FJD Early Phase Clin Trials Unit, Madrid, Spain
[3] UCI Hlth Chao Family Comprehens Canc Ctr, Med Dept, Orange, CA USA
[4] Inst Jules Bordet, Med Oncol Dept, Brussels, Belgium
[5] Clin Univ Navarra, Oncol Dept, Pamplona, Spain
[6] Begin Mil Teaching Hosp, Clin Res Unit, St Mande, France
[7] Hop Cochin AP HP, Paris, France
[8] South Texas Accelerated Res Therapeut START, Phase Trials, San Antonio, TX USA
[9] Univ Brescia, Med Oncol Dept, Brescia, Italy
[10] Sarah Cannon Res Inst, Lung Canc Res, Canc Ctr, Nashville, TN USA
[11] Hosp Univ Quironsalud Madrid, Oncol Dept, Pozuelo De Alarcon, Spain
[12] Ctr Hosp Reg Univ Lille, CHU Lille, Haut France, Lille, France
[13] CHI Creteil, Creteil, France
[14] Univ Milano Statale, UNIMI, Hematooncol Dept, Milan, Italy
[15] Merus NV, Biostat, Utrecht, Netherlands
[16] Merus NV, Translat Res, Utrecht, Netherlands
[17] Merus NV, Clin Operat, Utrecht, Netherlands
[18] Merus NV, Clin Dev, Utrecht, Netherlands
[19] Vall Hebron Univ Hosp, Lung Canc Unit, Med Oncol Serv, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.595
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
516MO
引用
收藏
页码：S1671 / S1671
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer
    Aguiar, Pedro N., Jr.
    Haaland, Benjamin
    Park, Wungki
    Tan, Pui San
    del Giglio, Auro
    Lopes, Gilberto de Lima, Jr.
    JAMA ONCOLOGY, 2018, 4 (08) : 1080 - 1084
  • [42] Efficacy and safety of Anti-EGFR TKIs combined with bevacizumab or ramucirumab in the first-line treatment of non-small cell lung cancer: Meta-analysis of randomized controlled trials
    Ergun, Y.
    Ucar, G.
    Acikgoz, Y.
    Dirikoc, M.
    Esen, S. Akturk
    Bardakci, M.
    Uncu, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S972 - S973
  • [43] Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
    Ramalingam, Suresh S.
    Yang, James C-H
    Lee, Chee Khoon
    Kurata, Takayasu
    Kim, Dong-Wan
    John, Thomas
    Nogami, Naoyuki
    Ohe, Yuichiro
    Mann, Helen
    Rukazenkov, Yuri
    Ghiorghiu, Serban
    Stetson, Daniel
    Markovets, Aleksandra
    Barrett, J. Carl
    Thress, Kenneth S.
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) : 841 - +
  • [44] Efficacy and Safety of Savolitinib for MET-Altered Non-Small Cell Lung Cancer (NSCLC) In First-Line Setting: A Case Series
    Hua, Y.
    Xu, W.
    Shi, H.
    Zheng, X.
    Li, X.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S652 - S653
  • [45] Predicting resistance to first-line osimertinib therapy for non-small cell lung cancer using a liquid biopsy gene panel
    Ito, Shin
    Tsurumi, Kyoji
    Shindo, Norihisa
    Souma, Satoshi
    Watanabe, Kana
    Suzuki, Aya
    Fukuhara, Tatsuro
    Yasuda, Jun
    CANCER SCIENCE, 2024, 115 : 1967 - 1967
  • [46] Efficacy and safety of nivolumab combined with standard therapies for first-line therapy of advanced non-small cell lung cancer
    Metzenmacher, Martin
    Christoph, Daniel C.
    JOURNAL OF THORACIC DISEASE, 2016, 8 (10) : E1254 - E1256
  • [47] Efficacy and Safety of Anlotinib in Combination with Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
    Han, B.
    Chu, T.
    Zhang, X.
    Zhong, H.
    Zhang, B.
    Wang, H.
    Gu, A.
    Zhang, W.
    Shi, C.
    Zhong, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S398 - S398
  • [48] Efficacy and Safety of Combing Anlotinib and Erlotinib as a First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Han, B.
    Chu, T.
    Shi, C.
    Zhong, H.
    Zhang, W.
    Zhang, B.
    Zhong, R.
    Zhang, X.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S646 - S647
  • [49] Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study
    Horinouchi, H.
    Goldman, J. W.
    Cho, B. C.
    Tomasini, P.
    Dunbar, M.
    Hoffman, D.
    Parikh, A.
    Blot, V.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2022, 33 : S1592 - S1592
  • [50] Local ablative therapy (LAT) for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib.
    Kim, Chul
    Roper, Nitin
    Hoang, Chuong D.
    Szabo, Eva
    Connolly, Maureen
    Padiernos, Emerson
    Kesarwala, Aparna Hemant
    Cultraro, Constance
    Waris, Maryam
    Gao, Shaojian
    Steinberg, Seth M.
    Wong, David T.
    Khan, Laved
    Rajan, Arun
    Guha, Udayan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345